8. AMGEN (Immunovex2, HSV-2)(2017): Recently purchased by Amgen from Biovex, Immunovex2 is intended as both therapeutic and preventive vaccine for HSV2. A Phase I study was started in February 2010, but completion and/or results are unknown. The bad news is that AMGEN bought Biovex mainly for its cancer drug, the good news is that AMGEN recently acknowledged the existence of Immunovex2 and briefly discussed it, sort of implying they are working on it. Also AMGEN has the money to back up any research study if it chooses to do so. The latest news was on March 7,2011(you will have to register to listen to this conference((it mentions and I quote “”It is interesting that we are able to remove two of the Herpes Simplex proteins”.)) )
http://www.wsw.com/webcast/cowen3/register.aspx?conf=cowen3&page=amgn&url=http%3A//www.wsw.com/webcast/cowen3/amgn/ , August 6, 2011: HC member JAY9876 stated “I spoke to the co-founder of Biovex, Robert Coffin, about 6 weeks ago and he mentioned phase II trials should begin around February/March 2012.”